Drug Discovery World

DECEMBER 14, 2023

Antibody drug conjugate MBRC-101 MBrace Therapeutics presented preclinical data demonstrating the potential of its novel antibody drug conjugate MBRC-101 for the treatment of solid tumours including hormone receptor-positive (HR+) and triple negative breast cancers. months in heavily pre-treated patients.

HR 52

HR Hormones Trials In-Vivo 52

The Pharma Data

DECEMBER 9, 2020

Our focus on partnering to accelerate patient access to innovative medicines underscores our commitment to advancing breakthroughs in biomedicine such as antibody drug conjugates, cell therapy, RNAi and more, Ed Zhang, company co-founder, chief operating and business officer, said in a statement.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

The Pharma Data

OCTOBER 14, 2020

VBL Therapeutics – The European Patent Office granted a patent to Israel-based VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat inflammatory conditions. All jobs have been maintained and the workforce has grown from about 220 to 350. AOP anticipates new opportunities in Austria as a hub for research and business.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52